These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1534 related articles for article (PubMed ID: 17470709)

  • 1. Clinical end points in coronary stent trials: a case for standardized definitions.
    Cutlip DE; Windecker S; Mehran R; Boam A; Cohen DJ; van Es GA; Steg PG; Morel MA; Mauri L; Vranckx P; McFadden E; Lansky A; Hamon M; Krucoff MW; Serruys PW;
    Circulation; 2007 May; 115(17):2344-51. PubMed ID: 17470709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium.
    Leon MB; Piazza N; Nikolsky E; Blackstone EH; Cutlip DE; Kappetein AP; Krucoff MW; Mack M; Mehran R; Miller C; Morel MA; Petersen J; Popma JJ; Takkenberg JJ; Vahanian A; van Es GA; Vranckx P; Webb JG; Windecker S; Serruys PW
    J Am Coll Cardiol; 2011 Jan; 57(3):253-69. PubMed ID: 21216553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry.
    Machecourt J; Danchin N; Lablanche JM; Fauvel JM; Bonnet JL; Marliere S; Foote A; Quesada JL; Eltchaninoff H; Vanzetto G;
    J Am Coll Cardiol; 2007 Aug; 50(6):501-8. PubMed ID: 17678732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation.
    Stone GW; Ellis SG; Colombo A; Dawkins KD; Grube E; Cutlip DE; Friedman M; Baim DS; Koglin J
    Circulation; 2007 Jun; 115(22):2842-7. PubMed ID: 17515458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical endpoints in peripheral endovascular revascularization trials: a case for standardized definitions.
    Diehm N; Pattynama PM; Jaff MR; Cremonesi A; Becker GJ; Hopkins LN; Mahler F; Talen A; Cardella JF; Ramee S; van Sambeek M; Vermassen F; Biamino G
    Eur J Vasc Endovasc Surg; 2008 Oct; 36(4):409-19. PubMed ID: 18692415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention.
    Kip KE; Hollabaugh K; Marroquin OC; Williams DO
    J Am Coll Cardiol; 2008 Feb; 51(7):701-7. PubMed ID: 18279733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.
    Morice MC; Serruys PW; Barragan P; Bode C; Van Es GA; Stoll HP; Snead D; Mauri L; Cutlip DE; Sousa E
    J Am Coll Cardiol; 2007 Oct; 50(14):1299-304. PubMed ID: 17903626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials: findings from the GHOST Study (Guthrie Health System Off-Label StenT Study).
    Harjai KJ; Orshaw P; Shenoy C; Acharji S; Sporn D; Aboufares A; Stapleton D
    J Interv Cardiol; 2008 Aug; 21(4):315-24. PubMed ID: 18754967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials.
    Kumbhani DJ; Bavry AA; Kamdar AR; Helton TJ; Bhatt DL
    Am Heart J; 2008 Apr; 155(4):640-7. PubMed ID: 18371470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of diabetes mellitus on early and long-term results of percutaneous drug-eluting stent implantation for unprotected left main coronary disease.
    Sheiban I; Garrone P; Sillano D; Biondi-Zoccai G; Sciuto F; Omedè P; Lombardi P; Meliga E; Anselmino M; Trevi GP; Moretti C
    J Cardiovasc Med (Hagerstown); 2008 Dec; 9(12):1246-53. PubMed ID: 19001932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design.
    Pfisterer M; Bertel O; Bonetti PO; Brunner-La Rocca HP; Eberli FR; Erne P; Galatius S; Hornig B; Kiowski W; Pachinger O; Pedrazzini G; Rickli H; De Servi S; Kaiser C;
    Am Heart J; 2008 Apr; 155(4):609-14. PubMed ID: 18371466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis.
    Pinto Slottow TL; Waksman R
    Catheter Cardiovasc Interv; 2007 Jun; 69(7):1064-74. PubMed ID: 17525967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation.
    Zellweger MJ; Kaiser C; Brunner-La Rocca HP; Buser PT; Osswald S; Weiss P; Mueller-Brand J; Pfisterer ME;
    J Nucl Med; 2008 Apr; 49(4):550-6. PubMed ID: 18344439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting stent safety.
    Slottow TL; Waksman R
    Am J Cardiol; 2007 Oct; 100(8B):10M-17M. PubMed ID: 17950827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
    Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
    J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative safety and efficacy of a sirolimus-eluting versus paclitaxel-eluting stent: a meta-analysis.
    Gurm HS; Boyden T; Welch KB
    Am Heart J; 2008 Apr; 155(4):630-9. PubMed ID: 18371469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
    Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
    Qasim A; Cosgrave J; Latib A; Colombo A
    Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.